A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
At a glance
- Drugs BMS 986094 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2013 Planned end date changed from 1 Jul 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.